Emerging evidence indicates that there are potential benefits when managing the cytokine storm in COVID-19 patients by administering steroids, IL-6/IL-6-receptor (IL-6R) blocking antibodies, TNF inhibitors, IL-1 antagonists, and Janus kinase inhibitor (JAK) inhibitors (62). The gene discussed is IL1B; the disease is COVID-19.